Coles AJ, Jones JL, Vermersch P, Traboulsee A, et al. Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. Mult Scler 2021 Dec 9:13524585211061335. doi: 10.1177/13524585211061335.
PMID: 34882037